Intracellular Peptide Delivery Reagent

Information

  • Research Project
  • 6486267
  • ApplicationId
    6486267
  • Core Project Number
    R43CA096198
  • Full Project Number
    1R43CA096198-01
  • Serial Number
    96198
  • FOA Number
  • Sub Project Id
  • Project Start Date
    4/15/2002 - 22 years ago
  • Project End Date
    2/28/2003 - 21 years ago
  • Program Officer Name
    SWAIN, AMY L
  • Budget Start Date
    4/15/2002 - 22 years ago
  • Budget End Date
    2/28/2003 - 21 years ago
  • Fiscal Year
    2002
  • Support Year
    1
  • Suffix
  • Award Notice Date
    4/15/2002 - 22 years ago

Intracellular Peptide Delivery Reagent

DESCRIPTION (provided by applicant): Although there are many very effective reagents available to introduce transcriptionally active DNA into viable cells, approaches to deliver functional peptides and proteins into living cells are limited. For this reason, we developed a lipid-mediated protein delivery reagent, called BioPORTER, which can deliver fluorescently labeled antibodies, functional enzymes (caspases and b-galactosidase) and other macromolecules into the cytoplasm of a variety of different adherent and suspension cells. Although BioPORTER is very effective for delivering many different macromolecules into cells it has some limitations. The lipid-mediated delivery system is not effective for delivering hydrophilic proteins and small peptides. For example, using BioPORTER we tried to deliver several peptides including, SV4O NLS and a p53 peptide, without success. Since synthetic peptides are readily available and have the potential to exert intracellular effects on viable cells, it is unfortunate that BioPORTER is not effective for this purpose. Therefore, the objective of this proposal is to understand why BioPORTER is less effective for peptide delivery, and to use this knowledge to engineer a modified reagent that is effective. A series of fluorescently labeled synthetic peptides will be synthesized with different physical properties and their intracellular uptake will be monitored by confocal microscopy and FACS analysis. The understanding gained from this analysis will be applied to the design of peptides and reagent compositions to demonstrate functional intracellular peptide delivery. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    178643
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:178643\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GENE THERAPY SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES